View in EDS HTML Full Text PDF Full Text

A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.

Saved in:

Bibliographic Details
Title:	A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.
Authors:	Wilfret, David A.¹, Walker, Jill¹, Voitenleitner, Christian¹, Baptiste‐Brown, Sharon¹, Lovern, Mark¹, Kim, Joseph¹, Adkison, Kimberly¹, Shotwell, Brad¹, Mathis, Amanda¹, Moss, Lee¹, Lee, Daniel¹, Yu, Lou¹, Gan, Jianjun¹, Spaltenstein, Andrew¹
Source:	Clinical Pharmacology in Drug Development. Nov2014, Vol. 3 Issue 6, p439-448. 10p.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Description
ISSN:	2160763X
DOI:	10.1002/cpdd.142